REMS Redesign: What FDA Heard From Stakeholders
This article was originally published in RPM Report
Executive Summary
CDER Associate Director for Policy Jane Axelrad chaired the two day stakeholder meeting on REMS July 27-28, and delivered a remarkably cogent summary of about 15 hours presentations and discussion before adjourning the event. Here is here summary of the key takeaways from the meeting, excerpted from the official FDA transcript of the event.
You may also be interested in...
The Era of Drug Efficacy
FDA has been perceived by drug developers as a regulator obsessed with drug safety. But recent cases show serious safety concerns aren’t holding back new products: efficacy has been the deciding factor for approval.
US FDA Alzheimer Guidance Update Reflects Changes In Biomarkers – And Leadership
Latest update to draft guidance on early Alzheimer’s drug development is the third iteration of a document first published in 2013. The history of the guidance is a reflection of structural and leadership changes in the neurology review team at FDA.
Biden’s Co-Pay Cap Is Silver Lining For Pharma In Drug Pricing Campaign
President Biden’s call to expand the US Medicare price negotiation program is naturally making headlines from his campaign-year State of the Union Address. But his call for a national cap on co-pays could be an important opportunity for industry in the years to come.